Lani
07-26-2007, 11:52 AM
Anticancer Res. 2007 Jul-Aug;27(4A):1963-8.
Importance of CEA and CA 15-3 during disease progression in metastatic breast cancer patients.
Laessig D, Nagel D, Heinemann V, Untch M, Kahlert S, Bauerfeind I, Stieber P.
Department of Internal Medicine III, University Hospital, Munich, Germany.
The aim of this study analysis was to determine the correlation between elevation of CEA and/or CA 15-3 and disease progression of metastatic breast cancer. MATERIALS AND METHODS: We investigated 119 breast cancer patients who had metachronous metastases. We evaluated levels of CEA and CA 15-3 at the time of first recurrence and at every further disease progression (PD). RESULTS: Increasing value levels of CEA as well as CA 15-3 were found in correlation to the number of PD with a continuously increasing sensitivity in the detection of metastatic disease for each marker alone and especially in combination. At the first time of distant metastasis, CEA and CA 15-3 were above the 95th percentile of healthy individuals in 53.5% and 71.8%, respectively. During disease progression the sensitivities were: 1st PD for CEA/ CA 15-3 54.1%/ 70.6%, 2nd PD 63.5%/ 81.2% and 3rd PD 68.6%/ 90%. CONCLUSION: There is a correlation between elevation of CEA and/or CA 15-3 and disease progression, in breast cancer patients.
PMID: 17649806 [PubMed - in process]
Importance of CEA and CA 15-3 during disease progression in metastatic breast cancer patients.
Laessig D, Nagel D, Heinemann V, Untch M, Kahlert S, Bauerfeind I, Stieber P.
Department of Internal Medicine III, University Hospital, Munich, Germany.
The aim of this study analysis was to determine the correlation between elevation of CEA and/or CA 15-3 and disease progression of metastatic breast cancer. MATERIALS AND METHODS: We investigated 119 breast cancer patients who had metachronous metastases. We evaluated levels of CEA and CA 15-3 at the time of first recurrence and at every further disease progression (PD). RESULTS: Increasing value levels of CEA as well as CA 15-3 were found in correlation to the number of PD with a continuously increasing sensitivity in the detection of metastatic disease for each marker alone and especially in combination. At the first time of distant metastasis, CEA and CA 15-3 were above the 95th percentile of healthy individuals in 53.5% and 71.8%, respectively. During disease progression the sensitivities were: 1st PD for CEA/ CA 15-3 54.1%/ 70.6%, 2nd PD 63.5%/ 81.2% and 3rd PD 68.6%/ 90%. CONCLUSION: There is a correlation between elevation of CEA and/or CA 15-3 and disease progression, in breast cancer patients.
PMID: 17649806 [PubMed - in process]